Inhibition of human gastric cancer growth by cytokine-induced killer cells plus chemotherapy with or without cadonilimab in a mouse xenograft tumor model.

Wenwei Yang, Jingwei Liu, Tiantian Hou, Xu Lu, Lin Yang

Abstract read

In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenwei Yang *Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Jingwei Liu *Department of Oncology, Karh Biohealthcare Biotechnology (Zhejiang) Co., Ltd., Jiaxing, China.

Tiantian Hou *National Center for Safety Evaluation of Drugs, Beijing Key Laboratory of Quality Control and Non-clinical Research and Evaluation for Cellular and Gene Therapy Medicinal Products, National Institutes for Food and Drug Control, Beijing, China.

Xu LuDepartment of Oncology, Karh Biohealthcare Biotechnology (Zhejiang) Co., Ltd., Jiaxing, China.

Lin YangDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cytokine-induced killer (CIK) cell therapy has shown potent antitumor cytotoxicity. To date, no study has evaluated the efficacy and safety of combining CIK cell therapy with chemotherapy, with or without the immune checkpoint inhibitor (ICI) cadonilimab, for treating gastric cancer (GC). Methods: Results: Conclusions: The combination of CIK cells and chemotherapy with or without ICIs can serve as a potential therapeutic option for treating GC, with promising efficacy and good tolerability.

Indexed as

Antibodies, Monoclonal, HumanizedCytokine-Induced Killer CellsImmune Checkpoint InhibitorsImmunotherapy, AdoptiveStomach NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred BALB CMice, NudeXenograft Model Antitumor AssaysAntibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitorschemotherapycombination therapycytokine-induced killer cellsgastric cancerimmune checkpoint inhibitorsmouse xenograft model

Identifiers

PMID40539041

DOI10.3389/fimmu.2025.1609320

PMCPMC12176880

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.